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Summary
Background Infants are a key target population for new tuberculosis vaccines. We assessed the safety and 
immunogenicity of the live-attenuated Mycobacterium tuberculosis vaccine candidate MTBVAC in adults and infants in 
a region where transmission of tuberculosis is very high.
Methods We did a randomised, double-blind, BCG-controlled, dose-escalation trial at the South African Tuberculosis 
Vaccine Initiative site near Cape Town, South Africa. Healthy adult community volunteers who were aged 
18–50 years, had received BCG vaccination as infants, were HIV negative, had negative interferon-γ release assay 
(IGRA) results, and had no personal history of tuberculosis or current household contact with someone with 
tuberculosis were enrolled in a safety cohort. Infants born to HIV-negative women with no personal history of 
tuberculosis or current household contact with a person with tuberculosis and who were 96 h old or younger, 
generally healthy, and had not yet received routine BCG vaccination were enrolled in a separate infant cohort. 
Eligible adults were randomly assigned (1:1) to receive either BCG Vaccine SSI (5 × 10⁵ colony forming units [CFU] 
of Danish strain 1331 in 0·1 mL diluent) or MTBVAC (5 × 10⁵ CFU in 0·1 mL) intradermally in the deltoid region of 
the arm. After favourable review of 28-day reactogenicity and safety data in the adult cohort, infants were randomly 
assigned (1:3) to receive either BCG Vaccine SSI (2·5 × 10⁵ CFU in 0·05 mL diluent) or MTBVAC in three sequential 
cohorts of increasing MTBVAC dose (2·5 × 10³ CFU, 2·5 × 10⁴ CFU, and 2·5 × 10⁵ CFU in 0·05 mL) intradermally in 
the deltoid region of the arm. QuantiFERON-TB Gold In-Tube IGRA was done on days 180 and 360. For both 
randomisations, a pre-prepared block randomisation schedule was used. Participants (and their parents or 
guardians in the case of infant participants), investigators, and other clinical and laboratory staff were masked to 
intervention allocation. The primary outcomes, which were all measured in the infant cohort, were solicited and 
unsolicited local adverse events and serious adverse events until day 360; non-serious systemic adverse events until 
day 28 and vaccine-specific CD4 and CD8 T-cell responses on days 7, 28, 70, 180, and 360. Secondary outcomes 
measured in adults were local injection-site and systemic reactions and haematology and biochemistry at study day 
7 and 28. Safety analyses and immunogenicity analyses were done in all participants who received a dose of vaccine. 
This trial is registered with ClinicalTrials.gov, number NCT02729571.
Findings Between Sept 29, 2015, and Nov 16, 2015, 62 adults were screened and 18 were enrolled and randomly 
assigned, nine each to the BCG and MTBVAC groups. Between Feb 12, 2016, and Sept 21, 2016, 36 infants were 
randomly assigned—eight to the BCG group, nine to the 2·5 × 10³ CFU MTBVAC group, nine to the 2·5 × 10⁴ CFU 
group, and ten to the 2·5 × 10⁵ CFU group. Mild injection-site reactions occurred only in infants in the BCG and the 
2·5 × 10⁵ CFU MTBVAC group, with no evidence of local or regional injection-site complications. Systemic adverse 
events were evenly distributed across BCG and MTBVAC dose groups, and were mostly mild in severity. 
Eight serious adverse events were reported in seven vaccine recipients (one adult MTBVAC recipient, one infant 
BCG recipient, one infant in the 2·5 × 10³ CFU MTBVAC group, two in the 2·5 × 10⁴ CFU MTBVAC group, and two 
in the 2·5 × 10⁵ CFU MTBVAC group), including one infant in the 2·5 × 10³ CFU MTBVAC group treated for 
unconfirmed tuberculosis and one in the 2·5 × 10⁵ CFU MTBVAC group treated for unlikely tuberculosis. One 
infant died as a result of possible viral pneumonia. Vaccination with all MTBVAC doses induced durable antigen-
specific T-helper-1 cytokine-expressing CD4 cell responses in infants that peaked 70 days after vaccination and were 
detectable 360 days after vaccination. For the highest MTBVAC dose (ie, 2·5 × 10⁵ CFU), these responses exceeded 
responses induced by an equivalent dose of the BCG vaccine up to 360 days after vaccination. Dose-related IGRA 
conversion was noted in three (38%) of eight infants in the 2·5 × 10³ CFU MTBVAC group, six (75%) of eight in the 
2·5 × 10⁴ CFU MTBVAC group, and seven (78%) of nine in the 2·5 × 10⁵ CFU MTBVAC group at day 180, compared 
with none of seven infants in the BCG group. By day 360, IGRA reversion had occurred in all three infants (100%) 
in the 2·5 × 10³ CFU MTBVAC group, four (67%) of the six in the 2·5 × 10⁴ CFU MTBVAC group, and three (43%) of 
the seven in the 2·5 × 10⁵ CFU MTBVAC group.
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Introduction
More than 1 million children develop tuberculosis every 
year, accounting for roughly 10% of the global burden of 
new disease.1 Most of these cases occur in countries with 
universal infant coverage of BCG vaccination.2 Infant 
BCG vaccination provides protection against severe 
disseminated forms of childhood tuberculosis, but 
efficacy and durability of protection against intrathoracic 
tuberculosis are highly variable.3–5 BCG vaccination 
might also provide some protection against all-cause 
infant mortality.6 Infants and children younger than 
5 years, who carry the greatest burden of severe morbidity 
and mortality caused by tuberculosis, are a priority target 
population for new vaccine develop ment.7,8 A new vaccine 
to replace or boost infant BCG vaccination is needed to 
provide consistent and durable protective immunity 
against tuberculosis in children and adults.8
Childhood vaccines based on live, whole, attenuated 
viruses or bacteria, such as the smallpox and measles 
vaccines, induce very long-lived protective immunity.9 
Evidence from a non-human primate model10 and a meta-
analysis11 of human studies from the pre-antibiotic era 
suggests that the host immune response induced by 
latent Mycobacterium tuberculosis infection confers 
protection against reinfection and subsequent active 
tuberculosis disease, which supports development of a 
live-attenuated M tuberculosis vaccine.
MTBVAC (which was developed at the University of 
Zaragoza [Zaragoza, Spain] and licensed to Biofabri 
[Pontevedra, Spain]) is a live, rationally attenuated 
clinical strain of M tuberculosis Euro-American lineage 4 
that has been genetically engineered to contain two 
independent unmarked stable deletion mutations in the 
virulence genes phoP and fadD26, without antibiotic 
resistance markers.12 The transcription factor PhoP 
regulates expression of 2% of the M tuberculosis genome, 
including production of immunomodulatory cell-wall 
lipids and secretion of the immunogenic protein 
ESAT-6.13 Deletion of fadD26 results in abrogation of 
synthesis of phthiocerol dimycocerosates, which are 
necessary for M tuberculosis virulence.14 MTBVAC thus 
has a similar protein, lipid, and carbohydrate antigen 
repertoire to virulent M tuberculosis, excluding those 
regulated by PhoP and coded by fadD26. MTBVAC 
contains all the M tuberculosis genes that are in the BCG 
vaccine, plus genes from Mycobacterium bovis that are 
deleted in the BCG vaccine. Of the 1603 experimentally 
validated human T-cell epitopes of M tuberculosis, 
433 (27%) are located in deleted regions that are absent 
from the BCG vaccine.12,15,16
Preclinical studies show comparable biodistribution 
and equivalent or improved safety and immuno gen-
icity for vaccination with MTBVAC as compared to 
BCG.12,17,18
Research in context
Evidence before this study
We searched PubMed by combining the terms “live”, 
“Mycobacterium tuberculosis”, “human”, and “vaccine” for original 
research articles and systematic reviews published in any language 
up to Feb 10, 2019. We identified only one published clinical trial 
of a live whole cell Mycobacterium tuberculosis vaccine, MTBVAC, 
which was done by Spertini and colleagues in BCG-naive Swiss 
adults. The safety of vaccination with MTBVAC was similar to that 
of BCG, and MTBVAC was at least as immunogenic as BCG.
Added value of this study
To our knowledge, ours is the first clinical trial of a live whole 
cell M tuberculosis vaccine to be done in BCG-vaccinated adults 
in a region where tuberculosis is endemic and in BCG-naive 
infants in any region. MTBVAC had similar safety and 
reactogenicity to BCG vaccination in infant participants. The 
highest MTBVAC dose tested (2·5 × 10⁵ colony-forming units) 
induced a response of greater magnitude than the equivalent 
dose of the BCG vaccine up to 360 days after vaccination. We 
noted a higher-than-expected frequency of dose-dependent 
positive interferon-γ release assay (IGRA) results in MTBVAC 
recipients.
Implications of all the available evidence
Our safety and immunogenicity results support the 
progression of MTBVAC to larger dose-defining studies and 
subsequent infant efficacy trials. Although dose-dependent 
IGRA conversion and reversion is an encouraging sign of 
immunogenicity, it might complicate future use of IGRA as a 
diagnostic tool for M tuberculosis infection in MTBVAC 
recipients. Future studies should attempt to differentiate the 
vaccine-induced response from that of natural M tuberculosis 
infection, define the mechanism and duration of IGRA 
cross-reactivity with MTBVAC, and apply stringent tuberculosis 
endpoint definitions independent of IGRA.
Interpretation MTBVAC had acceptable reactogenicity, and induced a durable CD4 cell response in infants. The 
evidence of immunogenicity supports progression of MTBVAC into larger safety and efficacy trials, but also confounds 
interpretation of tests for M tuberculosis infection, highlighting the need for stringent endpoint definition.
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Aguilo and colleagues hypothesised that MTBVAC 
could provide better protection against tuberculosis than 
the BCG vaccine because it induces immune responses 
to more M tuberculosis-specific antigenic targets.19 The 
mechanisms underlying BCG-induced immunological 
protection are incompletely understood.20 Although 
animal models have clearly shown that intact T-helper-1 
(Th1) immunity is necessary to control M tuberculosis,20 
human studies have not consistently shown an association 
between Th1 responses and risk of tuberculosis disease. 
A study21 of immune responses in infants in the MVA85A 
phase 2B trial22 suggested that increased numbers of 
BCG-reactive cells secreting interferon-γ (IFN-γ), as 
measured with the ELIspot assay, were associated with a 
reduced risk of developing tuberculosis. However, 
although the MVA85A vaccine induced long-lived, 
polyfunctional Th1 CD4 T cells that co-expressed IFN-γ, 
tumour necrosis factor α (TNFα), and interleukin 2 (IL-2), 
no vaccine efficacy was noted.22 Similarly, in a study23 of 
10-week-old infants who received BCG vaccination at 
birth, frequencies of BCG-reactive Th1 cells were not 
associated with subsequent risk of tuberculosis.
Preclinical and clinical development of MTBVAC 
was guided by the Second Geneva Consensus recom-
mendations for novel live TB vaccines.24 Infants are the 
primary target population for MTBVAC and other live 
mycobacterial vaccines, because, like the BCG vaccine, 
this class of vaccines has the potential to protect infants 
and children against both M tuberculosis infection and 
subsequent active tuberculosis disease.3,25,26 Vaccination of 
infants soon after birth might also circumvent masking 
or blocking effects against live-attenuated vaccines by 
previous mycobacterial sensitisation in older children 
and adults.3
MTBVAC was safe in newborn, SCID, and BALB/c 
mice and in guinea pigs.12,27 It was also safe and 
immunogenic in BCG-naive adults with negative results 
on a purified protein derivative skin test in Switzerland 
in three dose cohorts, who were injected with 5 × 10³, 
5 × 10⁴, and 5 × 10⁵ colony-forming units (CFU) in 
0·1 mL, respectively.28 However, the safety and 
immunogenicity of tuberculosis vaccines in infants 
cannot be directly inferred from adult studies, even 
those done in BCG-naive and M tuberculosis-naive 
populations.22,29 Infant and adult findings for cross-
reactivity between mycobacterial vaccines and common 
tests for M tuberculosis infection could also be 
discordant.28,30 Studies in older children and adults in 
countries where previous M tuberculosis exposure is 
common and BCG vaccination is universal could 
potentially misdirect assessment of potential harms and 
immunogenicity in infants. Thus, reliable safety and 
immunogenicity data to inform clinical development of 
live mycobacterial vaccines for infants have to be 
obtained from infant studies in tuberculosis-endemic 
countries. Here we report the findings of a dose-
escalation trial of MTBVAC in South African infants.
Methods
Study design and participants
We did a randomised, double-blind, BCG-controlled, 
dose-escalation trial of MTBVAC in South African 
infants, preceded by an adult safety cohort. The trial was 
done at the South African Tuberculosis Vaccine Initiative 
site near Cape Town, South Africa, where transmission 
of M tuberculosis is very high.26,31,32 Healthy adult 
community volunteers were enrolled in the adult safety 
cohort if they were aged 18–50 years, had received BCG 
vaccination as infants, were HIV negative (as measured 
with the Uni-Gold Recombigen HIV-1 and HIV-2 rapid 
test (Trinity Biotech, Bray, Ireland), with positive results 
confirmed by ELISA), had negative IFN-γ release assay 
(IGRA) results (measured with the Quantiferon-TB Gold 
In-Tube [QFT; Qiagen, Hilden, Germany] according to 
manufacturers’ instructions), and had no personal 
history of tuberculosis or current household contact with 
someone with tuberculosis. For the infant cohort, we 
approached HIV-negative women with no personal 
history of tuberculosis or current household contact with 
a person with tuberculosis at public antenatal clinics 
during their third trimester of pregnancy. Infants born to 
consenting women were eligible for inclusion in the trial 
if they were 96 h old or younger, generally healthy, 
weighed at least 2·45 kg, had 5-min Apgar scores of at 
least 7, were of 38 weeks’ gestation or longer, and had not 
yet received routine BCG vaccination. A full list of 
inclusion and exclusion criteria is available in the trial 
protocol. 
The trial protocol was approved by the South African 
Health Products Regulatory Authority and the University 
of Cape Town Human Research Ethics Committee. 
Written informed consent was obtained from adult 
participants before any study procedures, and from the 
mothers of infant participants before the onset of labour.
Randomisation and masking
Adults judged by investigators to be eligible for inclusion 
in the trial were enrolled and immediately randomly 
assigned (1:1) to receive BCG Vaccine SSI (Statens Serum 
Institut, Copenhagen, Denmark) or MTBVAC (Biofabri, 
Pontevedra, Spain). The study team used a pre-prepared 
block randomisation schedule that was generated off-site 
by the clinical research organisation TCD (Centurion, 
South Africa) in SAS (version 9.4), which linked treatment 
numbers to the allocated treatment. Study pharmacists 
allocated a treatment number (and corresponding treat-
ment) in ascending order sequentially as participants 
were enrolled.
After favourable review of 28-day reactogenicity and 
safety data in the adult cohort by an independent data 
and safety monitoring board, eligible infants were 
randomly assigned (1:3) to receive either BCG Vaccine 
SSI or MTBVAC in three sequential cohorts of increasing 
MTBVAC dose. Dose escalation between infant cohorts 
was dependent upon favourable review of 28-day data for 
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reactogenicity, adverse events, and serious adverse events 
by the data and safety monitoring board at the preceding 
MTBVAC dose level. The randomisation process in the 
infant cohort was the same that was used for the adult 
cohort. 
Participants and parents or carers were masked to 
group assignment. All vaccine syringes were prepared by 
the study pharmacist, masked by semitransparent tape, 
and administered by a vaccination nurse who was not 
involved in study safety assessments. Investigators and 
other clinical and laboratory staff who were involved 
in assessing outcomes and analysing data remained 
masked to adult intervention allocation until study 
completion. Clinical staff were unmasked to infant 
group allocation after 180  days’ follow-up, so that BCG 
vaccination could be offered to MTBVAC recipients per 
protocol. Laboratory staff remained masked to infant 
intervention assignment until all immunology data had 
been analysed.
Procedures
Adults were administered either BCG Vaccine SSI (5 × 10⁵ 
CFU of Danish strain 1331 in 0·1 mL diluent) or 
MTBVAC (5 × 10⁵ CFU in 0·1 mL) intradermally on study 
day 0 in the deltoid region of their non-dominant arm. 
Infants were administered either the BCG vaccine 
(2·5 × 10⁵ CFU in 0·05 mL diluent) or MTBVAC 
(2·5 × 10³ CFU, 2·5 × 10⁴ CFU, or 2·5 × 10⁵ CFU in 
0·05 mL) intradermally on day 0 in the deltoid region of 
their left arm. Follow-up visits were scheduled on study 
days 7, 14, 28, 56, 90, and 180 in the adult cohort, and on 
days 7, 14, 28, 70, 91, 180, and 360 in the infant cohort. In 
both groups, injection-site reactions were assessed at all 
visits. In the adult cohort, all adverse events were 
recorded until day 90 on diary cards and at follow-up 
visits. In the infant cohort, all adverse events were 
recorded until day 360 on diary cards, at follow-up visits 
and during any other contact with caregivers between 
follow-up visits. Haematological (full blood count, 
differential white cell count, and platelets) and 
biochemical (liver and renal function) analyses were 
done on days 7 and 28 in both cohorts. QFT IGRA was 
done on day 180 in both cohorts, and also on day 360 in 
the infant cohort.
Venous blood for immunogenicity outcomes was 
collected on days 7, 28, 70, 180, and 360 in the infant cohort. 
Immunogenicity of MTBVAC was assessed in infants by 
measuring frequencies of CD4 and CD8 T cells expressing 
antigen-specific IFN-γ, TNFα, IL-2, interleukin 17 (IL-17), 
or IL-22. Longitudinal T-cell response magnitudes after 
MTBVAC or BCG vaccination were measured in each 
infant by computing the total area under the response 
curve (AUC), allowing comparison between groups. We 
compared the change in antigen-specific response 
magnitude from baseline (day 7) to peak (day 70) and from 
baseline to day 360, the latter of which we defined as the 
memory response. We also measured vaccine-induced 
Figure 1: Trial profiles for the adult (A) and infant (B) cohorts
Safety monitoring continued for all infants until the end of the trial. IGRA=interferon-γ release assay. 
CFU=colony-forming units. DSMB=data and safety monitoring board. *Babies were born during a shortage of BCG, 
and thus study enrolment was paused. †One parent refused to allow blood to be drawn at all timepoints, and a parent 
of a second infant refused to allow blood to be drawn after day 7 (although the initial samples taken were included in 
immunogenicity analyses). ‡A parent of one infant refused to allow any further blood to be drawn after day 28. 
62 adults assessed for eligibility
18 enrolled and randomly assigned
9 assigned to MTBVAC (5x105 CFU) group 9 assigned to BCG SSI (5x105 CFU) group
9 completed study and included in safety analysis
9 assigned to MTBVAC 
 (2·5×103 CFU) group
9 assigned to MTBVAC 
 (2·5×104 CFU) group
10 assigned to MTBVAC 
 (2·5×105 CFU) group
8 assigned to BCG SSI 
 (2·5×105 CFU) group
9 completed study 8 completed study 10 completed study 8 completed study 
9 completed study and 
 included in safety 
 analysis; 8 included 
 in immunogenicity 
 analysis†
9 included in safety 
 analysis; 8 included 
 in immunogenicity 
 analysis
10 included in 
 safety and 
 immunogenicity 
 analyses‡
8 included in 
 safety and 
 immunogenicity 
 analyses
9 completed study and included in safety analysis
44 not enrolled
 31 had positive IGRA results
 5 HIV positive
 3 had abnormal blood results
 3 assessed after enrolment target reached
 1 was lactating
 1 future problems with phlebotomy anticipated
117 infants assessed for eligibility
1 died before 
 day 28
36 enrolled and randomly assigned
81 not enrolled
 34 born during DSMB review
 10 BCG unavailable*
 9 received BCG at birth
 6 assessed after enrolment target reached
 6 mothers withdrew consent before delivery
 4 had low birthweight
 4 premature (<38 weeks' gestation) 
 4 maternal pregnancy abnormalities
 1 older than 96 h
 1 hypoglycaemic at birth
 1 had a household tuberculosis contact
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immune responses on days 180 and 360 with an IGRA 
incorporating the M tuberculosis-specific antigens ESAT-6 
and CFP-10.
All infants were screened actively for risk factors and 
symptoms compatible with tuberculosis disease at each 
visit. Infants with new symptoms, household tuberculosis 
contacts, or positive IGRA test conversion (which was 
defined as >0·35 international units IFN-γ per mL) were 
referred to the clinic for assessment of possible tuberculosis 
disease and provision of free curative treatment or 
isoniazid preventive therapy as indicated. After unblinding 
at day 180, infant MTBVAC recipients were offered catch-
up BCG vaccination. Active tuberculosis surveillance 
ended at the day 360 visit, after which passive tuberculosis 
surveillance by telephone contact continued until infants 
were aged 2 years.
Outcomes
The primary aims of the trial were to assess the safety, 
reactogenicity, and immunogenicity of three different 
doses of MTBVAC compared with BCG in infants. The 
primary safety and reactogenicity outcomes were 
solicited and unsolicited local adverse events and serious 
adverse events until day 360, and non-serious systemic 
adverse events until day 28. These outcomes were 
assessed by recording local injection-site reactions 
(erythema, ulceration, induration, swelling, tenderness, 
drainage, scarring, axillary or cervical lymphadenopathy, 
and abscess formation), solicited systemic adverse events 
(fever, irritability, myalgia, headache, changes in feeding 
patterns, lethargy, skin rash, weight loss, and failure to 
thrive), and other unsolicited systemic adverse events up 
to day 360. Adverse events and serious adverse events are 
reported by study group and MTBVAC dose group, and 
were classified by severity and relationship to the 
intervention.
Primary immunogenicity outcomes were antigen-
specific CD4 and CD8 T-cell responses on days 7, 28, 70, 
180 and 360, which were measured by whole blood 
intracellular cytokine staining as previously described,33 
after stimulation with MTBVAC (1 × 10⁶ CFU per mL 
blood), a pool of 122 peptides of immunodominant 
M tuberculosis epitopes (MegaPool [Genscript, 
Piscataway, NJ, USA];34 1 µg/mL per peptide), 
phytohaemagglutinin (R30852801 [Thermo Fisher 
Scientific, Waltham MA, USA; 5 µg/mL), or media 
(unstimulated control). Details of the assay procedures 
are in the appendix (pp 1–3).
Safety and reactogenicity in adults, which were 
assessed before infant recruitment, were secondary 
outcomes, and were assessed by recording local injection-
site and systemic reactions (including malaise, fever, 
myalgia, headache, and skin rash). Haematological and 
biochemical parameters at day 7 and 28 were compared 
with baseline in adults and infants.
The protocol was amended on Dec 23, 2016, to allow 
for assessment of the potential for MTBVAC to cross-
react with the M tuberculosis antigens ESAT-6 and CFP-10 
as a secondary outcome, which was measured by IGRA 
in both age groups. A full list of all outcomes is provided 
in the trial protocol. The protocol also details procedures 
for grading the severity of adverse events.
See Online for appendix
BCG group (5 × 10⁵ 
colony-forming 
units; n=9)
MTBVAC group (5 × 10⁵ 
colony-forming 
units; n=9)
Age, years 28·4 (8·1) 29·4 (8·2)
Height, cm 160·8 (5·5) 162·0 (7·1)
Weight, kg 63·9 (19·6) 85·2 (26·0)
BMI, kg/m² 24·7 (7·3) 32·3 (9·2)
Sex
Female 7 (78%) 8 (89%)
Male 2 (22) 1 (11%)
Race
Black 3 (33%) 3 (33%)
Cape mixed ancestry 6 (67%) 6 (67%)
Current smoker 5 (56%) 1 (11%)
Data are mean (SD) or n (%).
Table 1: Baseline demographics in the adult safety cohort
BCG group (5 × 10⁵ 
colony-forming 
units; n=9)
MTBVAC group (5 × 10⁵ 
colony-forming 
units; n=9)
Participants with at least 
one adverse event
9 (100%) 9 (100%)
Adverse events 97 93
Solicited adverse events 65 60
Severity*
Mild 90 (93%) 78 (84%)
Moderate 7 (7%) 13 (14%)
Severe 0 2 (2%)
Relationship to vaccine*
Not related 5 (5%) 10 (11%)
Related 92 (95%) 83 (89%)
Serious adverse events 0 1 (11%)
Local solicited adverse events*
Erythema 9 (100%) 7 (78%)
Injection-site swelling 9 (100%) 9 (100%)
Injection-site exfoliation 5 (56%) 8 (89%)
Systemic solicited adverse events*
Headache 5 (56%) 4 (44%)
Malaise 3 (33%) 1 (11%)
Myalgia 2 (22%) 2 (22%)
Unsolicited adverse events 
Fatigue 3 (33%) 2 (22%)
Injection-site scarring 9 (100%) 8 (89%)
Data are n or n (%). This table lists common adverse events of interest and 
summarises severity, relationship to vaccine and seriousness of adverse events. 
A table showing all adverse events is in the appendix (p 4). *Participants were 
counted once at the highest severity level in each dose group; percentages are 
calculated on the basis of the total number of adverse events. 
Table 2: Adverse events in the adult safety cohort
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Statistical analysis
The sample size was selected for preliminary assessment 
of the safety profile of MTBVAC in infants. Sample size 
selection was based on similar trials designed for 
preliminary assessment of the type and frequency of 
adverse events in vaccine recipients, and the trial was not 
Demographics Dose cohort Time since 
vaccination 







(5 × 10⁵ CFU)
100 days History of headache, 





syndrome and Enterovirus 
meningitis were differential 
diagnoses)
Positive HIV ELISA, 4·1 × 10⁹ white cells per 
L, CRP 4 mg/L, IGRA at day 180 negative, 
chest radiograph normal. CSF contained 
119 mmol/L chloride, 2·8 mmol/L glucose, 
0·64 g/L protein, six polymorphonuclear 
lymphocytes per μL, and 64 lymphocytes 
per μL; repeat CSF sample taken 3 days later 
contained 118 mmol/L chloride, 2·4 
mmol/L glucose, 1·35 g/L protein, and no 
cells; original CSF was India ink stain 
negative, both samples were Gram stain 
negative and neither showed bacterial 
growth after 2 days; initial CSF Xpert 
MTB/RIF negative, CSF MGIT culture 
insufficient
Unlikely Patient was discharged after 5 days when 
asymptomatic and with no neurological 
sequelae. She received a standard 
tuberculosis regimen for 6 months, and 
then started antiretroviral therapy. The 
patient was well at the end of the study, 








(2·5 × 10⁴ CFU)
9 days History of jaundice. 
Neonatal jaundice 
diagnosed
Total serum bilirubin 326 µmol/L Unrelated Jaundice resolved with phototherapy, 
but participant died age 29 days 







(2·5 × 10⁴ CFU)
27 days Short history of runny nose, 
lethargy,and poor feeding; 
unresponsive, apneic, and 
declared dead on arrival at 
hospital. Possible viral 
pneumonia diagnosed
An academic autopsy revealed no evidence 
of mycobacterial infection (no injection-site 
or local lymph node reactions, and no foamy 
macrophages, granulomas, or caseous 
necrosis on microscopy; Ziehl Neelsen 
staining of lung, liver, and spleen samples 
were negative for acid-fast bacilli)
Unlikely Death




2·5 × 10³ CFU)
365 days History of recurrent 
pneumonia that did not 
resolve with intravenous 
antibiotics, and failure to 
thrive; household 
tuberculosis contact. 
Aspiration pneumonia and 
gastro-oesphophagal reflux 
disease provisionally 
diagnosed; classified as 
unconfirmed tuberculosis
23·5 × 10⁹ white cells per L, IGRA at days 
180 and 360 negative, chest radiograph 
showed perihilar opacification, right middle 
lobe infiltrates, and honeycombing, 
bronchoscopic bronchoalveolar lavage 
contained no organisms (auramine stain 
negative) and 18·5% lipid-laden 
macrophages. Two gastric washings and 
two induced sputum samples were taken 
on consecutive days: all samples negative 
on auramine staining, Xpert MTB/RIF, and 
MGIT culture
Unrelated Tuberculosis treatment was started 
(standard regimen), but the infant was 
subsequently treated for two episodes 
of pneumonia with no improvement in 
appearance of chest radiographs. 
Tuberculosis treatment was continued, 
and patient was well after 6 months; 






(2·5 × 10⁵ CFU)
6 months History of diarrhoea, 
pyrexia, and dehydration; 
no symptoms of 
tuberculosis. Dysentery 
diagnosed; classified as 
unlikely tuberculosis
IGRA positive at day 180 but negative at 
day 360, gastric washing samples negative 
on auramine staining, Xpert MTB/RIF, and 
MGIT culture, chest radiograph showed 
patchy infiltrates in the right lung and 
perihilar lymphadenopathy suggestive of 
tuberculosis.
Unrelated Dysentery responded rapidly to 
rehydration and intravenous 
antibiotics. Tuberculosis treatment was 
started on the basis of chest radiograph 
but mother stopped giving infant her 
tuberculosis treatment after 2 weeks; 
infant was healthy and thriving off 
treatment for the next 18 months
B042 9-day-old boy 
(birthweight 
3065 g)
BCG 2 days History of diffuse pustular 
rash. Diffuse staphylococcal 
rash diagnosed
IGRA negative at days 180 and 360, light 
growth of Staphylococcus aureus in pus 
swab, Gram positive cocci in blood culture
Unrelated Thriving at end of study




(2·5 × 10⁴ CFU)




CRP 55 mg/L, 7·9 × 10⁹ white cells per L, 
IGRA negative at days 180 and 360, chest 
radiograph showed right-sided infiltrates
Unrelated Responded rapidly to intravenous 
antibiotics; well at end of study




(2·5 × 10⁵ CFU)





CRP 1mg/L, 16·9 × 109 white cells per L, 
IGRA negative at days 180 and 360, 
Gram positive cocci in blood culture, chest 
radiograph showed bronchopneumonia 
and increased patchiness in left upper lobe
Unrelated Responded well to intravenous 
antibiotics; well at end of study
CFU=colony-forming units. CRP=C-reactive protein. IGRA=interferon γ release assay. MGIT=Mycobacteria Growth Indicator Tube.
Table 3: Serious adverse events and immediately reportable events in the adult and infant cohorts, by participant identifier
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powered to detect rare or uncommon adverse events, or to 
define the frequency of adverse events precisely by study 
arm or MTBVAC dose. Safety and immunogenicity 
analyses were done in all participants who received a 
dose of vaccine according to a prespecified statistical 
analysis plan). This plan contains details of all statistical 
calculations done for this trial.
The data and safety monitoring board, operating by 
charter, considered comparative frequencies and relative 
risk of serious adverse events, grade 3 or 4 adverse events 
for reactogenicity and systemic adverse events, and 
trends in adverse events within and between study 
groups. It also met ad hoc to review any safety issues of 
concern, including possible cases of tuberculosis, infant 
deaths, and IGRA conversion data.
We used Prism (version 8) or R (version 4.3) for all 
analyses. The trial was registered at ClinicalTrials.gov, 
number NCT02729571.
Role of the funding source
Biofabri had roles in study design, data interpretation, 
and writing of the report, but not in data collection or 
data analysis. The Norwegian Agency for Development 
Cooperation had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between Sept 29, 2015, and Nov 16, 2015, 62 adults were 
screened and 18 were enrolled and randomly assigned, 
nine each to the BCG and MTBVAC groups (figure 1A). 
Both groups had similar demographics at baseline, but 
body-mass index was higher in the MTBVAC group 
than in the BCG group (table 1). All 18 participants 
completed all study visits. The frequency, severity, 
and type of adverse events were similar between 
the two groups (table 2). The most frequent local 
injection-site reactions were swelling, erythema, and 
injection-site scarring, most of which were mild 
(table 2; appendix p 4). Systemic reactions were mostly 
mild to moderate (appendix p 4), with headache, 
malaise, and myalgia the most common solicited events 
(table 2). No vaccine-related severe adverse events or 
serious adverse events were recorded.
One serious adverse event occurred in an adult 
MTBVAC recipient but was judged to be unrelated to the 
vaccine. She was diagnosed with newly acquired HIV 
infection (with 378 CD4 cells per µL) and aseptic 
meningitis 3 months after vaccination (table 3). She 
rapidly and completely recovered from the aseptic 
meningitis after treatment with empirical broad-
spectrum antibiotics and anti-tuberculous therapy for 
possible tuberculous meningitis, and was discharged 
from hospital after 5 days with no neurological sequelae 
typical of tuberculous meningitis.35,36 She had negative 
IGRA results on day 180, but completed 6 months’ 
treatment for possible tuberculous meningitis before 
starting antiretroviral therapy, and remains well with 
undetectable HIV viral load. Two (22%) adult MTBVAC 
recipients had positive IGRA at day 180, but were 
asymptomatic and had no known tuberculosis contacts. 
A favourable review of 28-day adult safety data by the data 
and safety monitoring board enabled progression to 
infant recruitment.
Between Feb 12, 2016, and Sept 21, 2016, 117 pregnant 
women consented to partake in the trial, and 36 infants 
were enrolled (figure 1B, table 4). Eight (22%) infants 
were assigned to the BCG group and 28 (78%) were 
assigned to the MTBVAC groups – nine (25%) each to 
the 2·5 × 10³ CFU and 2·5 × 10⁴ CFU doses, and 
ten (28%) to the 2·5 × 10⁵ CFU dose. A worldwide 
distribution shortage of the BCG Vaccine SSI 
necessitated a protocol amendment (on Dec 23, 2016) 
and revision of the informed consent document so that 
the final six infants enrolled in the third dose cohort 
(ie, 2·5 × 10⁵ CFU) could receive open-label MTBVAC, 
which resulted in the slight deviation from the 
randomisation ratio in group numbers. Follow-up was 
completed on Sept 11, 2017, with 35 infants completing 
the study (one infant died).
Local injection-site reactions, most frequently 
swelling, erythema, and scarring, were recorded only in 
the BCG and high-dose MTBVAC (ie, 2·5 × 10⁵ CFU) 
groups, and were mild in severity (table 5; appendix pp 
5–6). No local or regional lymphadenopathy or 
ulceration were reported. Systemic adverse events were 
evenly distributed across all four study groups (table 5), 
and were mostly mild in severity (appendix pp 5–6). 
The most frequent solicited systemic adverse events 
were failure to thrive, irritability, and pyrexia (table 5). 
The most common unsolicited systemic adverse event 
was upper respiratory tract infection (table 5). Seven 
For the statistical analysis plan 
see https://zivahub.uct.ac.za/
s/992494159c4f55dd4d92




2·5 × 10³ 
colony-forming 
units (n=9)
2·5 × 10⁴ 
colony-forming 
units (n=9)
2·5 × 10⁵ 
colony-forming 
units (n=10)
Age, days 1·9 (1·1) 2·2 (1·3) 1·6 (0·7) 1·5 (0·7)
Length, cm 49·0 (3·0) 49·4 (1·6) 48·3 (3·3) 47·6 (1·7)
Weight, kg 3·21 (0·49) 2·98 (0·23) 3·06 (0·57) 2·95 (0·37)
Sex
Female 5 ( 63%) 4 (44%) 5 (56%) 9 (90%)
Male 3 (38%) 5 (56%) 4 (44%) 1 (10%)
Race
Black 2 (25%) 1 (11%) 3 (33%) 5 (50%)
Cape mixed ancestry 6 (75%) 8 (89%) 6 (67%) 5 (50%)
Data are mean (SD) or n (%).
Table 4: Baseline demographics in the infant cohort
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serious adverse events were reported, including one 
death (in an MTBVAC recipient at age 4 weeks), but 
none of these events were judged to be related to study 
treatment. An autopsy showed changes suggestive of 
viral pneumonia and possible liver disease with 
cholestasis, and the pathologist concluded that the 
cause of death was not related to mycobacterial 
infection (table 3).
One infant was treated for unlikely tuberculosis and 
one for unconfirmed tuberculosis (as defined by 
Graham and colleagues37) during active study follow-up 
(ie, up to day 360; table 3). No children were treated 
for tuberculosis during the second year of passive 
follow-up.
Immunology analyses were completed in 26 of the 
28 infants in the MTBVAC group. One infant, who 
received the lowest dose of MTBVAC, was not included 
because their parents withdrew consent for blood 
sampling. One infant died and thus was not included. 
Figure 2 shows the frequencies of CD4 and CD8 T cells 
expressing antigen-specific IFN-γ, TNFα, IL-2, IL-17, or 
IL-22 (appendix pp 7–12). Vaccination with all doses of 
MTBVAC and with BCG vaccine, primed a CD4 T-cell 
response comprising Th1 cells that primarily expressed 
IFN-γ, TNF-α, or IL-2, or a combination thereof, and 
peaked 70 days after vaccination in all groups (figure 2B; 
appendix pp 7–12). MTBVAC-specific T-helper-22 (Th22) 
CD4 cells (producing IL-22), T-helper-17 (Th17) CD4 cells 
(producing IL-17), and cytokine-expressing CD8 cells 
were low or undetectable in most participants (figure 2B; 
appendix pp 7–12). Thus, we focused on CD4 cell co-
expression patterns of IFN-γ, TNF-α, and IL-2 in 
subsequent analyses.
AUCs for MTBVAC-specific CD4 cells expressing 
any cytokine, Th1-cytokine-positive CD4 cells, and poly-
functional Th1 CD4 cells suggested a significant difference 
between the four groups, whereas AUCs for MTBVAC-
specific Th22 CD4 cells, Th17 CD4 cells, and cytokine-
expressing CD8 T cells did not differ significantly between 
groups (figure 2B). Direct comparison of MTBVAC-specific 
response magnitudes between dose groups showed a dose-
dependent increase in cytokine-expressing CD4 cells at 
days 70, 180, and 360 (figure 2C). Vaccination with the 
highest dose of MTBVAC also induced significantly higher 
frequencies of MTBVAC-specific CD4 T cells at days 70 and 
day 360 than the equivalent dose of BCG (figure 2C).
Antigen-specific responses measured at days 70 and 
360 were not higher than baseline responses in infants 
BCG group 
(2·5 × 10⁵ CFU; 
n=8)
MTBVAC groups
2·5 × 10³ 
colony-forming 
units (n=9)
2·5 × 10⁴ 
colony-forming 
units (n=9)
2·5 × 10⁵ 
colony-forming 
units (n=9)
Participants with at least 
one adverse event
8 (100%) 9 (100%) 9 (100%) 10 (100%)
Adverse events 67 44 33 67
Solicited adverse events 26 2 5 13
Severity*
Mild 59 (88%) 34 (77%) 27 (82%) 62 (93%)
Moderate 5 (7%) 7 (16%) 5 (15%) 5 (7%)
Severe 3 (4%) 3 (7%) 1 (3%) 0
Relationship to vaccine*
Not related 29 (43%) 37 (84%) 32 (97%) 44 (66%)
Related 38 (57%) 7 (16%) 1 (3%) 23 (34%)
Serious adverse events 1 (1%) 1 (2%) 3 (9%) 2 (3%)
Local solicited adverse events
Injection-site erythema 4 (50%) 0 0 1 (10%)
Injection-site swelling 6 (75%) 0 0 8 (80%)
Injection-site pustule 3 (38%) 0 0 0
Systemic solicited adverse events
Failure to thrive 1 (13%) 2 (22%) 2 (22%) 1 (10%)
Irritability 3 (38%) 0 2 (22%) 0
Pyrexia 1 (13%) 0 1 (11%) 0
Unsolicited adverse events
Upper respiratory tract infection 3 (38%) 6 (67%) 3 (33%) 6 (60%)
Papular rash 3 (38%) 2 (22%) 3 (33%) 5 (50%)
Increased alkaline phosphatase 
concentrations
1 (13%) 2 (22%) 4 (44%) 5 (50%)
Diaper dermatitis 3 (38%) 2 (22%) 3 (33%) 4 (40%)
Injection-site scarring 7 (88%) 0 0 5 (50%)
Data are n or n (%). This table lists common adverse events of interest and summarises severity, relationship to vaccine, 
and seriousness of adverse events, by study groups. A table showing all adverse events is in the appendix (pp 5–6). 
*Participants were counted once at the highest severity level in each dose group; percentages are calculated on the basis 
of the total number of adverse events.
Table 5: Adverse events in the infant cohort
Figure 2: Kinetics of total T-cell responses induced by vaccination
(A) Representative flow cytometry dot plots showing cytokine production by 
CD4 cells in unstimulated and MTBVAC-stimulated blood collected at day 70 
from a representative infant vaccinated with 2·5 × 10⁵ CFU of MTBVAC 
(appendix pp 7–12). Blood was stimulated with MTBVAC and frequencies of 
cytokine-expressing cells from the unstimulated control were subtracted from 
antigen-specific frequencies. (B) Longitudinal kinetics of antigen-specific CD4 or 
CD8 cells expressing the indicated cytokine responses in participants after 
vaccination and measured by whole blood intracellular cytokine staining assay. 
The lines depict median frequencies of cytokine-expressing CD4 or CD8 cells; 
error bars depict IQRs for each dose group. p values are for inter-group 
comparisons (with the Kruskal-Wallis test) of the area under the response curve, 
which was calculated for each infant. Blood was stimulated with MTBVAC and 
frequencies of cytokine-expressing cells from the unstimulated control were 
subtracted from antigen-specific frequencies. (C) Frequencies of antigen-specific 
CD4 cell responses on days 70, 180, and 360 (end of study). The horizontal lines 
represent medians, boxes show the IQR, and error bars show the range. p values 
for between-group comparisons were computed with the Mann-Whitney U test. 
Individual participant responses and antigen-specific responses to stimulation 
with a peptide pool of 122 Mycobacterium tuberculosis immunodominant 
epitopes are in the appendix (pp 7–12). CFU=colony-forming units. 
TNFα=tumour necrosis factor α. IL-2=interleukin 2. IFN-γ=interferon-γ. 
IL-17=interleukin 17. IL-22=interleukin 22. Th1=T-helper-1. Th22=T-helper-22. 
Th17=T-helper-17. *Co-expression of any combination of IFN-γ, TNFα, IL-2, 
IL-17, and IL-22. †Expression of any combination of IFN-γ, TNFα, and IL-2. 
‡Co-expression of IFN-γ, TNF-α, and IL-2. §p values <0·05 for which the 
corresponding q value, as calculated with the Benjamini and Hochberg false 
discovery rate method, was also <0·05 (see appendix p 11 for actual p values).
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who received the 2·5 × 10³ CFU dose of MTBVAC 
(figure 3A). By contrast, the 2·5 × 10⁴ CFU and 
2·5 × 10⁵ CFU doses induced increased responses at day 
360 compared with baseline (figure 3A; appendix p 12). 
Cytokine co-expression patterns of MTBVAC-specific 
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predominantly polyfunctional (figure 3B; appendix 
p 12).
Dose-related IGRA conversion was noted in three (38%) 
of eight infants in the 2·5 × 10³ CFU MTBVAC dose group, 
six (75%) of eight in the 2·5 × 10⁴ CFU MTBVAC dose 
group, and seven (78%) of nine in the 2·5 × 10⁵ CFU 
MTBVAC dose group at day 180, whereas IGRA conversion 
was noted in none of the seven infants in the BCG group 
who were tested (figure 3C). A known new household 
tuberculosis contact was reported by three MTBVAC 
recipients, one of whom became IGRA positive at 6 
months. All infants who tested IGRA positive were 
referred for tuberculosis investigation and possible 
isoniazid preventive therapy as soon as conversion was 
detected. 16 of the 17 infants who were referred received 
isoniazid preventive therapy. By day 360, IGRA reversion 
had occurred in all three infants (100%) in the low-dose 
group, four (67%) of the six in the medium-dose group, 
and three (43%) of the seven in the high-dose group (42·8%) 
in whom IGRA conversion had been recorded. No new 
IGRA conversions were noted at day 360 (Figure 3C).
Discussion
We showed that the live-attenuated M tuberculosis 
vaccine MTBVAC had an acceptable reactogenicity 
profile at doses ranging from 2·5 × 10³ to 2·5 × 10⁵ CFU 
in both M-tuberculosis-uninfected adults and newborn 
infants in a setting with a high tuberculosis burden. 
Local and systemic adverse events occurred in the 
highest dose (2·5 × 10⁵ CFU) group at a similar 
frequency as in the BCG vaccination group. There was 
no evidence of local or regional injection-site 
complications. MTBVAC induced antigen-specific Th1 
immune responses that peaked around 10 weeks and 
established a durable memory response that persisted 
1 year after vaccination, and at a magnitude greater than 
the equivalent dose of BCG. An unexpected dose-related 
effect of MTBVAC on IGRA conversion and subsequent 
reversion was also noted, and occurred at a higher 
frequency than was noted previously in BCG-naive 
Swiss adults28 and in the BCG-vaccinated South African 
adults in this trial. This observation, although providing 
supportive evidence that MTBVAC induces durable 
T-cell responses, confounds interpretation of IGRA as a 
test for M tuberculosis infection and as evidence of 
M tuberculosis exposure that would typically be used to 
support clinical diagnosis of tuberculosis disease in 
children.
This trial was not designed to test efficacy of MTBVAC, 
but given that the effect of MTBVAC on the risk of 
tuberculosis disease is unknown, any possible cases are 
of interest. In our trial, an adult MTBVAC recipient was 
diagnosed with new HIV infection and aseptic 
meningitis consistent with possible tuberculous 
meningitis.36 However, she had negative IGRA and CSF 
Xpert MTB/RIF results and a normal chest radiograph, 
and recovered completely and rapidly without typical 
neurological sequelae, findings that do not support this 
diagnosis. Differential diagnoses included HIV sero-
conversion syndrome, consistent with her aseptic CSF 
profile. Two infant MTBVAC recipients were also 
treated, one for unlikely tuberculosis and one for 
unconfirmed tuberculosis, by the public health services,37 
but neither diagnosis was convincing. The proportion of 
infant MTBVAC recipients with clinically diagnosed but 
unconfirmed tuberculosis in our trial (ie, two [7%] out 
of 28) was similar to that in a previous trial in this 
community (9%) in which more than 90% of these 
diagnoses were unconfirmed.22,39
Trials of live attenuated mycobacterial vaccines such 
as MTBVAC present a unique challenge in that the 
investigational product and the M tuberculosis pathogen 
are very similar strains, and specific molecular methods 
would be necessary to differentiate the two if samples 
from a site of disease were cultured. Clinicians in 
countries with high burdens of tuberculosis have a 
high index of suspicion for clinical tuberculosis 
diagnosis and a low threshold for starting treatment in 
children. The obvious dilemma for safety reporting, 
attribution of causality, and tuberculosis case ascertain-
ment is that it is impossible to prove that MTBVAC is 
not the causative agent of unconfirmed disease in the 
absence of a speciated, cultured isolate. Thus, vaccine 
strain disease cannot be conclusively disproven. This 
challenge is magnified in paediatric trials, in which 
most childhood tuberculosis cases are not micro-
biologically confirmed.22,39
Because MTBVAC is a live attenuated vaccine, there is 
a theoretical risk of strain dissemination from the site of 
injection, however unlikely, in any participant with 
mycobacterial disease. This possibility has been tested in 
preclinical studies in immunocompetent and immuno-
suppressed animal models. In immunocompetent 
Balb/C mice intradermally inoculated with MTBVAC, no 
toxic effects were noted, organ biodistribution and 
Figure 3: Magnitude, durability, and quality of antigen-specific T-cell 
responses
(A) Frequencies of antigen-specific CD4 T cells producing any combination of 
IFN-γ, TNFα, IL-2, IL-17, or IL-22 detected after MTBVAC stimulation of blood 
from each infant at day 7 (ie, baseline), day 70 (top panels), and day 360 
(bottom panels). Each set of dots connected by a line represents an infant. 
p values are for a comparison of baseline to day 70 or day 360, and were 
calculated with the Wilcoxon matched-pairs signed rank test. (B) CD4 cell 
co-expression patterns of IFN-γ, TNFα, and IL-2 at day 70 (peak response) 
and day 360 (end of study), arranged from left to right by the degree of T-cell 
differentiation according to Seder and colleagues.38 The horizontal lines 
represent medians, boxes show the IQR, and error bars show the range. 
No statistical analysis was done. The appendix (p 9) shows the same analysis 
detected after stimulation of blood with a peptide pool of 
122 Mycobacterium tuberculosis immunodominant epitopes. (C) IFN-γ 
concentrations at days 180 and 360, as measured by the QuantiFERON-TB-Gold 
Gold In-Tube (Qiagen, Hilden, Germany) IFN-γ release assay. Each line represents 
data for one participant. IFN-γ=interferon-γ. TNFα=tumour necrosis factor α. 
IL-2=interleukin 2. IL-17=interleukin 17. IL-22=interleukin 22. 
CFU=colony-forming units.
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persistence were limited, and the vaccine strain was 
untraceable in urine and stools up to 6 months after 
vaccination, similar to the profile of BCG Vaccine SSI in 
Balb/C mice.12 The robust safety and attenuation profile 
of the doubly attenuated phoP-deficient and PDIM-
deficient phenotype has also been shown in two SCID 
mouse models with the MTBVAC prototype vaccine 
SO2.12,17
The BCG vaccine is a live attenuated mycobacterial 
vaccine that was originally derived from pathogenic 
M bovis, which causes tuberculosis disease in cattle. 
Autopsy studies show that BCG vaccination can be 
accompanied by asymptomatic bacteraemia.40,41 Distant 
and disseminated BCG disease that mainly affects 
immunocompromised infants and infants with HIV is 
rare but has been well described.40,42,43 It is estimated to 
affect two of every million vaccinees,44 and as many as 
992 of every 100 000 vaccinated immunocompromised 
infants.44 BCG disease is usually characterised by 
injection-site abscess and ipsilateral lymph node 
enlargement or lymphadenitis, and dissemination to 
distant organs is associated with high mortality in 
infants with HIV.42 Historical reports of the so-called 
Lubeck disaster (1929–33),45 when infants were given a 
BCG vaccine preparation that was accidentally 
contaminated with virulent wild-type M tuberculosis, 
also describe disseminated disease that was usually 
related to the route of vaccine administration.45 Safety 
studies have not been done to establish whether 
MTBVAC can also cause vaccine strain bacteraemia, 
but the known risk factors for, and clinical presentation 
of, BCG disease are useful to inform surveillance for 
the possibility of MTBVAC vaccine strain disease. We 
might expect vaccine strain disease to be rare in 
immunocompetent infants, to usually involve local and 
regional spread from the injection site to ipsilateral 
lymph nodes and systemic dissemination to bone 
marrow, lungs, and other organs (which would be 
associated with high mortality).
None of the MTBVAC recipients in this trial showed 
evidence of pathology at the site of injection or regional 
lymph nodes. The MTBVAC strain grows in standard 
liquid Mycobacteria Growth Indicator Tube culture and 
solid mycobacterial culture media, including Lowenstein-
Jensen medium, and is susceptible to first-line 
tuberculosis drugs, including isoniazid, ethambutol, 
streptomycin, and rifampicin.12 All PCR-based diagnostic 
methods, including Xpert MTB/RIF, that detect 
M tuberculosis on the basis of IS6110 or 16RNA should 
give a positive result for MTBVAC. However, none of the 
MTBVAC recipients treated for tuberculosis in this 
trial tested positive by mycobacterial culture or Xpert 
MTB/RIF. Therefore, in the absence of clinical features 
consistent with local, regional, or systemic dissemination, 
the mild clinical course of participants diagnosed with 
unconfirmed tuberculosis, the diagnoses of other 
illnesses in these patients, and the absence of laboratory 
evidence for mycobacterial disease of any kind, including 
wild-type M tuberculosis, we do not consider MTBVAC 
vaccine strain dissemination to be a reasonable possibility 
in this trial.
We observed a dose-dependent Th1 CD4 cell response to 
MTBVAC, which persisted to the end of active follow-up. 
In recipients of the 2·5 × 10⁵ CFU dose, the peak response 
to MTBVAC (ie, on day 70) was higher than that to the 
BCG vaccine, and responses on day 360 were higher for 
MTBVAC than BCG. Day 70 and day 360 Th1 CD4 cell 
responses to the low dose (2·5 × 10³ CFU) of MTBVAC 
were significantly lower than responses to BCG or the 
high MTBVAC dose. On the basis of these immunogenicity 
results, the low MTBVAC dose could be omitted from 
future studies. Although our immuno genicity results are 
encouraging and warrant further testing of MTBVAC, 
interpretation of our findings is limited by the small 
sample size (ie, eight to ten individuals per dose). In view 
of the dose-dependent response and acceptable safety 
profile, higher doses of MTBVAC could be explored in 
future studies. Two expanded dose-finding trials of 
MTBVAC, one in adults (NCT02933281) and one in 
infants (NCT03536117), are enroling participants.
We also noted an unexpectedly high frequency of dose-
related IGRA conversion in infant MTBVAC recipients, 
suggesting induction of T-cell responses to the antigens 
ESAT-6 or CFP-10, or both. MTBVAC expresses both of 
these antigens, but only CFP-10 is secreted.19 Transient, 
low-level CFP-10 responses were detected by IFN-γ 
ELISpot assay in three (11%) of 27 BCG-naive Swiss 
adults who received MTBVAC in a previous trial,28 and 
IGRA conversion was noted in two (22%) of 
nine previously BCG-vaccinated adult MTBVAC 
recipients in our trial. This occurrence, which is 
analogous to BCG causing false-positive tuberculin skin 
test results, could be interpreted as an encouraging sign 
of the immunogenicity of MTBVAC in BCG-naive and 
M tuberculosis-unexposed infants.
A study19 in mice suggested that the MTBVAC-
induced CFP-10-specific response might be necessary 
for vaccine-induced protection against M tuberculosis 
challenge. However, because IGRA is a diagnostic test 
for M tuberculosis infection, it is crucial that the 
dynamics and duration of MTBVAC-induced IGRA 
conversion are explored fully and that vaccine-induced 
conversion can be differentiated from M tuberculosis-
induced conversion. In this trial, IGRA conversion in 
infants who received MTBVAC prompted prescription 
of isoniazid preventive therapy because natural 
M tuberculosis infection could not be excluded. The high 
frequency of IGRA conversion noted in infants who 
received high MTBVAC doses was not expected on the 
basis of the adult data.28 Based on these results, a 
positive IGRA result soon after MTBVAC administration 
should not be used to diagnose M tuberculosis infection 
or as the basis for prescription of isoniazid preventive 
therapy, unless the positive IGRA result occurs for the 
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first time after the peak post-vaccination response has 
waned—ie, after 70 days.
MTBVAC is a unique candidate in the clinical 
development pipeline because it is the only live 
tuberculosis vaccine that contains the whole antigen 
repertoire of M tuberculosis, including the major antigens 
ESAT-6 (produced but not secreted in MTBVAC because 
of the phoP deletion) and CFP10 (produced and secreted 
in MTBVAC; unaffected by the phoP deletion).19 
Individuals with latent M tuberculosis infection who are 
reactive to CFP-10 and ESAT-6 stimulation seem to be 
more protected against reinfection with tuberculosis 
disease than individuals who have never been infected 
with M tuberculosis.11
The safety and immunogenicity data that we report 
here support the further clinical development of 
MTBVAC, through dose-ranging studies in infant and 
adult populations, in preparation for efficacy trials in 
countries where tuberculosis is endemic. Future clinical 
trials of MTBVAC should incorporate careful clinical 
assessment of injection-site complications, including 
swabs of any discharge, and sampling from other sites 
of suspected pathology for mycobacterial culture and 
differentiation of wild-type M tuberculosis and MTBVAC. 
The deletions in phoP and fadD26 in MTBVAC can be 
detected with a reverse transcriptase PCR presence–
absence approach designed for the differentiation 
of MTBVAC from wild-type M tuberculosis isolates. 
Vaccine-induced IGRA conversion, analogous to the 
vaccine-induced seroconversion that occurs in HIV 
vaccine trials, will further complicate the inherent 
difficulty of childhood tuberculosis diagnosis. Enhanced 
tuberculosis screening and stringent endpoint deter-
mination, independent of the current generation of 
IGRAs, will be crucial for future efficacy trials of 
MTBVAC in infants.22 Equally, infants with vaccine-
induced IGRA conversion must be protected against 
unnecessary TB investigations and therapy. Infants who 
test IGRA positive soon after vaccination with MTBVAC 
in contexts when natural M tuberculosis infection is 
unlikely should receive a card at the end of study stating 
that they have received an experimental vaccine that 
could interfere with interpretation of future IGRA and 
tuberculin skin tests.
Clearly, if MTBVAC is shown to offer better protection 
than the BCG vaccine against tuberculosis disease in 
efficacy trials, as suggested by preclinical studies,19,27 
the data from our trial will be important to support 
development of alternative diagnostic tests for 
M tuberculosis infection that are not cross-reactive with 
MTBVAC. For example, a CFP-10-free IGRA would be a 
useful diagnostic for MTBVAC vaccinees.
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